GLP1R and type 2 diabetes mellitus: Six GLP-1 analogs are commercially available as monotherapies for T2DM and are divided into shorting-acting exenatide and lixisenatide, long-acting liraglutide and prolonged-acting exenatide LAR, albiglutide and dulaglutide, based on the duration of action and frequency of injection [3].